Literature DB >> 23235135

Early routine versus late selective surfactant in preterm neonates with respiratory distress syndrome on nasal continuous positive airway pressure: a randomized controlled trial.

Hemasree Kandraju1, Srinivas Murki, Sreeram Subramanian, Pramod Gaddam, Ashok Deorari, Praveen Kumar.   

Abstract

BACKGROUND: Preterm neonates with respiratory distress syndrome (RDS) benefit from early application of nasal continuous positive airway pressure (nCPAP). However, it is not clear whether surfactant should be administered early as a routine to all such infants or later in a selective manner.
OBJECTIVE: It was the aim of this study to compare the efficacy of early routine versus late selective surfactant treatment in reducing the need for mechanical ventilation (MV) during the first week of life among moderate-sized preterm infants with RDS being supported by nCPAP.
METHODS: Infants born at 28(0/7) to 33(6/7) weeks of gestation with RDS and on nCPAP were randomly assigned within the first 2 h of life to early routine surfactant administration by the InSurE technique (early surfactant group) or to late selective administration of surfactant (late surfactant group). The primary outcome was need for MV in the first 7 days of life.
RESULTS: Among 153 infants randomized to early (n = 74) or late surfactant (n = 79) groups, the need for MV was significantly lower in the early surfactant group (16.2 vs. 31.6%; relative risk 0.41, 95% confidence interval 0.19-0.91). The incidence of pneumothorax (1.9 vs. 2.3%) and the need for supplemental O2 at 28 days (2.7 vs. 8.9%) were similar in the two groups.
CONCLUSION: Early routine surfactant administration within 2 h of life as compared to late selective administration significantly reduced the need for MV in the first week of life among preterm infants with RDS on nCPAP.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23235135     DOI: 10.1159/000345198

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  8 in total

1.  A new clinical respiratory distress score for surfactant therapy in preterm infants with respiratory distress.

Authors:  Debasish Nanda; Sushma Nangia; Anu Thukral; C P Yadav
Journal:  Eur J Pediatr       Date:  2019-12-18       Impact factor: 3.183

Review 2.  The use of surfactant in the neonatal period- the known aspects, those still under research and those which need to be investigated further.

Authors:  Nilgün Kültürsay; Özgün Uygur; Mehmet Yalaz
Journal:  Turk Pediatri Ars       Date:  2014-03-01

Review 3.  Use of CPAP and surfactant therapy in newborns with respiratory distress syndrome.

Authors:  Srinivas Murki; Ashok Deorari; Dharmapuri Vidyasagar
Journal:  Indian J Pediatr       Date:  2014-04-12       Impact factor: 1.967

4.  Evaluation of a practice guideline for the management of respiratory distress syndrome in preterm infants: A quality improvement initiative.

Authors:  Brooke Read; David Sc Lee; Debbie Fraser
Journal:  Paediatr Child Health       Date:  2016 Jan-Feb       Impact factor: 2.253

Review 5.  Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?

Authors:  Emmanuel Lopez; Géraldine Gascoin; Cyril Flamant; Mona Merhi; Pierre Tourneux; Olivier Baud
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

Review 6.  Efficacy and safety of surfactant replacement therapy for preterm neonates with respiratory distress syndrome in low- and middle-income countries: a systematic review.

Authors:  M J Sankar; N Gupta; K Jain; R Agarwal; V K Paul
Journal:  J Perinatol       Date:  2016-05       Impact factor: 2.521

Review 7.  Golden hour of neonatal life: Need of the hour.

Authors:  Deepak Sharma
Journal:  Matern Health Neonatol Perinatol       Date:  2017-09-19

8.  Prehospital administration of surfactant to a premature neonate in respiratory distress.

Authors:  Charles Haviland Mize; Lhab Dorji; Ken Zafren
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2019-10-29       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.